Fluconazole 2mg/ml Solution for Infusion
Adults Treatment of mycoses caused by Candida , Cryptococci and other susceptible yeasts, in particular: • Systemic candidiasis (including disseminated deep infections and peritonitis) • Severe mucosal candidiasis (including oropharyngeal candidiasis, oesophageal candidiasis and non-invasive bronchopulmonary candidiasis), where oral treatment is not possible. • Cryptococcal meningitis in adults • Prophylaxis against deep Candida infections (especially Candida albicans ) in patients with neutropenia due to bone marrow transplantation. Consideration should be given to official guidance on the appropriate use of antifungal agents. Before initiating treatment samples should be taken for microbiological analysis and the suitability of the therapy should subsequently be confirmed (see sections 4.2 and 5.1). In some patients with severe cryptococcal meningitis the mycological response during fluconazole treatment may be slower compared to other treatments (see section 4.4). Children and adolescents Treatment of mycoses caused by Candida and other susceptible yeasts, in particular: • Systemic candidiasis (including disseminated deep infections and peritonitis) • Severe mucosal candidiasis (including oropharyngeal candidiasis, oesophageal candidiasis and non-invasive bronchopulmonary candidiasis), where oral treatment is not possible. Consideration should be given to official guidance on the appropriate use of antifungal agents. Before initiating treatment samples should be taken for microbiological analysis and the suitability of the therapy should subsequently be confirmed (see sections 4.2 and 5.1).
